Concepedia

Author

Tillman Pearce

Threshold Pharmaceuticals (United States)ORCID

Also Known As

T E Pearce, T. Pearce, Tillman E Pearce, Tillman E. Pearce, Tillman Pearce

62

Publications

1.5K

Citations

16

H-Index

44

Concepts

All Affiliations

Threshold Pharmaceuticals (United States)Universitair Ziekenhuis LeuvenStanford UniversityThe University of Texas MD Anderson Cancer CenterMcGill University
TP

About

Tillman Pearce is an author at Threshold Pharmaceuticals (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

579

2

Engineering

1

1

106

3

Health Sciences

1

1

38

4

Allergy

1

1

36

5

Biostatistics

1

1

106

Tillman Pearce

×

16

Publications

1.1K

Citations

14

H-Index

YearCitations

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine,

The Lancet Oncology

2017

293

Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

Walter Reinisch, W de Villiers, László Bene,

Inflammatory Bowel Diseases

2009

215

Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa

Bruno François, Charles‐Édouard Luyt, Anthony Dugard,

Critical Care Medicine

2012

180

Convergence of evolving artificial intelligence and machine learning techniques in precision oncology

Elena Fountzilas, Tillman Pearce, Mehmet A. Baysal,

npj Digital Medicine

2025

106

Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia

R T Dorr, Chatchada Karanes, Catherine Spier,

Journal of Clinical Oncology

2001

82

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

Kathryn Evans, Jianxin Duan, Tara Pritchard,

Clinical Cancer Research

2019

51

Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia

Talha Badar, Damian Handisides, Juliana M. Benito,

American Journal of Hematology

2016

38

Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease

Daniël W. Hommes, Tatiana Mikhajlova, S Stoĭnov,

Gastroenterology

2004

36

Virus-cell membrane fusion does not predict efficient infection of alveolar macrophages by human immunodeficiency virus type 1 (HIV-1)

Mary Jane Potash, Michael Zeira, Zheng-Bo Huang,

Virology

1992

28

TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC.

Adam V. Patterson, Shevan Silva, Christopher P. Guise,

Journal of Clinical Oncology

2015

20

Page 1